You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

63 search results for: chronic inflammation

The Prevalence and Burden of Type 2 <b>Inflammation</b> in Patients With CRSwNP

expert video

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

8 min

Rhinology

Dr. Stella Lee educates on the immune responses mediating CRSwNP and the prevalence of type 2 inflammation.

IFOS 2023 | Type 2 <b>Inflammation</b> and Clinically Relevant Improvements in CRSwNP

expert video

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

42 min

Rhinology

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

The Pathophysiology of Type 2 <b>Inflammation</b> in CRSwNP

interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

5 min

Rhinology

Learn how type 2 inflammation underlies the pathophysiology of CRSwNP

Connecting Type 2 <b>Inflammation</b> to CRSwNP

expert video

Connecting Type 2 Inflammation to CRSwNP

1 min

Rhinology

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

expert video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

42 min

Pulmonology

Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.

IRS-ISIAN 2024 | Targeting Type 2 <b>Inflammation</b>: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

9 min

Rhinology

Prof. Joaquim Mullol reports on biologic improvements in sense of smell and nasal congestion in patients with and without a history of endoscopic sinus surgery.

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or <b>inflammation</b>?

expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

5 min

Rhinology

Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP

Targeting Underlying <b>Inflammation</b> in CRSwNP, a Type 2 Inflammatory Disease

expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

10 min

Rhinology

Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.

What Do We Know About Type 2 <b>Inflammation</b> in COPD?

expert video

What Do We Know About Type 2 Inflammation in COPD?

1 min

Pulmonology

Join global expert Dr. Michael Wechsler as he discusses type 2 inflammation in COPD.

Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

5 min

Dermatology

An infographic summarizing the clinical manifestations and pathophysiological processes of PN.

How Does Protective Type 2 Immunity Become Harmful Type 2 <b>Inflammation</b>?

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IsraelChange country/region